Y-90 radiolabelled Ibritumomab tiuxetan
Procedure description:
Used for the treatment of adult patients with rituximab-relapsed or refractory CD20+ follicular B-cell non-Hodgkins lymphoma (NHL). The Ibritumomab Tiuxetan antibody targets the CD20 antigen which is expressed on the surface of normal and malignant B-lymphocytes.
Indications:
For the treatment of adult patients with rituximab-relapse or refractory CD20+ follicular B-cell NHL.